Endocrinology
Researchers in France have found that aldosterone receptor antagonists can prevent cardiovascular disease and nephropathy in diabetic patients. The study, published in Diabetes and Metabolism, suggests that these molecules can be used to prevent or treat end-organ damage, particularly in patients with heart failure, diabetic nephropathy, and certain forms of
Endocrinology
Diabetic mice exhibit resistance to prostaglandin D2 synthase inhibition of cell cycle progression and migration of vascular smooth muscle cells. Recent research has shed light on the regulation of vascular smooth muscle cell proliferation, migration, and apoptosis, highlighting its role in the atherosclerotic process. Scientists in the United States have
Endocrinology
Researchers from the United States have made a breakthrough discovery regarding the hormone estrogen's effects on the human cervix. The study, led by R. Zeng and colleagues from the University Hospitals of Cleveland, found that estrogen reduces transcervical tight junctional resistance by accelerating the modulation of the tight
Endocrinology
A recent study from the University of Milan has found a significant association between menopausal status and an increased risk of metabolic and cardiovascular diseases, particularly in obese women. The study, published in the Journal of Endocrinological Investigation, analyzed the anthropometric, hormonal, and biochemical characteristics of 92 female outpatients, divided
Endocrinology
Type 1 diabetes research has been a focal point in the scientific community, particularly regarding the role of vitamin D in modulating the immune system. Recent studies have suggested that vitamin D administration may reduce the risk of type 1 diabetes, but the exact mechanisms and gene sequence variants involved
Endocrinology
Researchers have shed new light on the function of neuronal gluco-sensing in diabetes, a phenomenon where specialized cells in the brain use glucose as a signaling molecule to regulate energy homeostasis and other biological functions. Investigation by Barry E. Levin and his team at New Jersey Medical School has highlighted
Endocrinology
In a recent study published in Angiology, researchers in Greece investigated left ventricular function in 24 elderly patients with type 2 diabetes, who were asymptomatic and had no history of hypertension, coronary or valvular heart disease. The study found that left ventricular systolic and diastolic indices were impaired in these
Endocrinology
Nastech Pharmaceutical Company Inc. has announced the signing of separate agreements with two undisclosed research partners to evaluate the development of proprietary formulations for the nasal delivery of compounds useful for the treatment of type 2 diabetes and Alzheimer disease. The company will utilize its proprietary Tight Junction technology to
Endocrinology
The international medical community gathered at the 30th Annual Meeting of the International Society for Paediatric & Adolescent Diabetes (ISPAD 2004) in Singapore expressed concern over the growing problem of type 2 diabetes in children, particularly in the Asia-Pacific region. Professor Warren Lee, an expert on diabetes in Asia, emphasized
Endocrinology
Diabetic cardiomyopathy, a condition characterized by interstitial fibrosis, is a prominent issue in patients with diabetes. According to researchers, hyperglycemia and hyperinsulinemia are common root causes of this pathology, which is often a result of type 2 diabetes mellitus. This condition has the highest incidence of cardiovascular morbidity and mortality.
Endocrinology
A study from the United States has discovered that indinavir, an HIV protease inhibitor, increases fasting glucose levels and worsens hepatic insulin sensitivity in healthy HIV-uninfected men. After four weeks of treatment, researchers found that fasting glucose production and glycogenolysis were significantly increased, and indinavir blunted the ability of insulin
Endocrinology
Decision Resources, a leading research and advisory firm, has forecast that Eli Lilly's launch of ruboxistaurin in 2006 will revolutionize the diabetic neuropathy drug market from a focus on pain control to disease modification. According to the new Pharmacor study, "Diabetic Neuropathy," ruboxistaurin has the potential
